Navigating the complex terrain of hepatitis B virus reactivation in the era of Bruton tyrosine kinase inhibitors  

作　　者：Wei-Nung Liu Ming-Shen Dai Felicia Lin Gen-Min Lin 

机构地区：[1]Department of Medicine,Tri-Service General Hospital,Taipei 114,Taiwan [2]Division of Hematology/Oncology,Department of Internal Medicine,National Defense Medical Center,Taipei 114,Taiwan [3]Community Care,Minnesota Oncology,Minneapolis,MN 55404,United States [4]Department of Medicine,Hualien Armed Forces General Hospital,Hualien City 970,Taiwan

出　　处：《World Journal of Gastroenterology》2024年第21期2748-2750,共3页世界胃肠病学杂志（英文版）

摘　　要：In this editorial,we offer a summary of the risk associated with hepatitis B reactivation(HBVr)in the setting of both solid and hematologic malignancies treated with Bruton tyrosine kinase(BTK)inhibitors,with insights derived from current studies.Furthermore,we emphasize the critical need for a framework regarding robust risk evaluation in patients undergoing such treatments.This framework is essential for identifying those at increased risk of HBVr,enabling healthcare providers to implement proactive measures to prevent reactivation and ensure the safe administration of BTK inhibitor therapy.

关 键 词：Hepatitis B virus reactivation Bruton tyrosine kinase inhibitors Hematologic malignancies Solid tumors Prophylaxis guidelines 

分 类 号：R512.62[医药卫生—内科学]